Further support shown for cardiovascular safety for DPP-4 sitagliptin at ESC

ORAL diabetes agent sitagliptin (Januvia) demonstrated cardiovascular safety in patients with type 2 diabetes with pre-existing cardiovascular disease and heart failure, according to results from a large multinational trial.1